Canada’s Drug Agency is announcing recent and upcoming changes to the leadership of our Canadian Drug Expert Committee (CDEC), pan-Canadian Oncology Drug Review Expert Review Committee (pERC), and Patient and Community Advisory Committee (PCAC).
Dr. Peter Jamieson has been appointed incoming Chair…
Canada’s Drug Agency is launching a new 1-year learning period in our Scientific Advice program that will expand the type of guidance we offer to drug manufacturers to include those that are seeking advice after a “do not reimburse” recommendation is issued for their product.
During the learning…
New guidance from an expert panel offers recommendations on minimum retesting intervals for 5 laboratory tests that are commonly repeated in hospitals, health authorities, and community laboratories across the country.
The guidance may help these organizations implement strategies that support the…
In mid-March, we identified a cybersecurity incident in which an external party gained access to an application in our IT systems. We discovered the incident after an alarm was triggered. We immediately undertook countermeasures to prevent any further unauthorized access or activity and…
Registration is now open for Symposium 2024, a flagship event in the health technology assessment (HTA) community.
Symposium 2024 will be held on September 4 to 6, 2024, and offers both in-person networking and virtual attendance options. The in-person program will take place at the Shaw Centre in…
Health Canada’s Notice of Compliance with conditions (NOC/c) policy has been effective in providing people in Canada with faster access to new oncology drugs based on promising data. A retrospective cohort analysis published in the Canadian Journal of Health Technologies substantiates this by…
As part of our ongoing initiative to improve and modernize our reimbursement review program, Canada’s Drug Agency is introducing the first phase of process improvements related to companion diagnostics.
A companion diagnostic is a class of medical device used alongside a drug that is essential…
Canada’s Drug Agency has published a new report on an economic modelling approach used in evaluations of tumour-agnostic drugs that treat cancer.
The introduction of tumour-agnostic drugs continues to impact cancer treatment and brings additional complexity to the health technology assessment (HTA…
We are pleased to share our official IDEA Statement, recently approved by our Board of Directors and Executive Leadership Team.
This statement demonstrates our commitment to integrating inclusion, diversity, equity, and accessibility (IDEA) into our work within health systems, representing…
In December 2023, it was announced that Canada’s Drug Agency would be built from CADTH. The work of the drug agency expands on CADTH’s existing mandate and functions — which spans drugs, medical devices, and clinical interventions — and includes new work streams such as:
improving the appropriate…
A Statement From Suzanne McGurn, President and CEO, CADTH
On behalf of the organization and our Board of Directors, I’m pleased to share the Annual Report for 2023–2024.
The theme this year, Partnering for Results, aligns with our Strategic Plan and demonstrates how meaningful partnerships are…
Target Zero is a new initiative that aims to improve the time to access for patients in Canada for new drugs that are proven to be effective.
The ambitious goal of Target Zero is to achieve zero days between Health Canada’s regulatory approval of a drug and CADTH’s reimbursement recommendation to…